Advanced search
Publication Cover
Leukemia & Lymphoma Volume 41, 2001 - Issue 1-2
Submit an article Journal homepage
51
Views
43
CrossRef citations to date
0
Altmetric
Original Article

A Phase II Multicenter Study of CAMPATH-1H Antibody in Previously Treated Patients with Nonbulky Non-Hodgkin's Lymphoma

A. Khorana Roswell Park Cancer Institute, Buffalo, NY
,
P. Bunn University Of Colorado Cancer Center, Denver, CO
,
P. McLaughlin University of Texas, MD Anderson Cancer Center, Houston, TX
,
J. Vose University of Nebraska Medical Center, Omaha, NE, USA
,
C. Stewart Roswell Park Cancer Institute, Buffalo, NY
&
M. S. Czuczman Roswell Park Cancer Institute, Buffalo, NY
Pages 77-87 | Received 15 Jul 2000, Published online: 01 Jul 2009

Citations (43)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

William M. Siders, Jacqueline Shields, Carrie Garron, Yanping Hu, Paula Boutin, Srinivas Shankara, William Weber, Bruce Roberts & Johanne M. Kaplan. (2010) Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leukemia & Lymphoma 51:7, pages 1293-1304.
Read now
Eva Geissinger, Irina Bonzheim, Sabine Roth, Andreas Rosenwald, Hans Konrad Müller-Hermelink & Thomas Rüdiger. (2009) CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies. Leukemia & Lymphoma 50:6, pages 1010-1016.
Read now
Eric T Wong. (2005) Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm. Expert Opinion on Pharmacotherapy 6:7, pages 1107-1114.
Read now
George J Weiner & Brian K Link. (2004) Monoclonal antibody therapy of B cell lymphoma. Expert Opinion on Biological Therapy 4:3, pages 375-385.
Read now

Articles from other publishers (39)

Kamal Sharma, John E. Janik, Deirdre O'Mahony, Donn Stewart, Stefania Pittaluga, Maryalice Stetler-Stevenson, Elaine S. Jaffe, Mark Raffeld, Thomas A. Fleisher, Cathryn C. Lee, Seth M. Steinberg, Thomas A. Waldmann & John C. Morris. (2017) Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1–Associated Adult T-cell Leukemia/lymphoma. Clinical Cancer Research 23:1, pages 35-42.
Crossref
Thomas Elter, Michael Hallek & Janice M. Reichert. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies 1323 1374 .
Neerav Shukla, Rachel Kobos, Thomas Renaud, Julie Teruya‐Feldstein, Anita Price, Linda McAllister‐Lucas & Peter Steinherz. (2011) Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab. Cancer 118:15, pages 3719-3724.
Crossref
Robert O. Dillman. (2011) Cancer Immunotherapy. Cancer Biotherapy and Radiopharmaceuticals 26:1, pages 1-64.
Crossref
Francisco J. Hernandez-Ilizaliturri & Myron S. Czuczman. 2011. Management of Hematologic Malignancies. Management of Hematologic Malignancies 338 366 .
Adam Abdool, Chen-Hsiung Yeh, Hagop Kantarjian, Susan O'Brien, Jean Marie Bruey, Francis Giles & Maher Albitar. (2010) Circulating CD33 and its clinical value in acute leukemia. Experimental Hematology 38:6, pages 462-471.
Crossref
Stephen Ansell. 2009. Emerging Protein Biotherapeutics. Emerging Protein Biotherapeutics.
John G. Gribben & Michael Hallek. (2009) Rediscovering alemtuzumab: current and emerging therapeutic roles. British Journal of Haematology 144:6, pages 818-831.
Crossref
Robert O. Dillman. 2009. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy 303 406 .
I Hus, M Schmitt, J Tabarkiewicz, S Radej, K Wojas, A Bojarska-Junak, A Schmitt, K Giannopoulos, A Dmoszyńska & J Roliński. (2008) Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 22:5, pages 1007-1017.
Crossref
Thomas S. Lin. (2007) Mechanisms of Alemtuzumab-Mediated Cytotoxicity in Hematologic Malignancies. Clinical Leukemia 1:3, pages 168-171.
Crossref
Thomas Elter, Andreas Engert & Michael Hallek. 2007. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies 733 777 .
Richard R. Furman, John P. Leonard, Julian Decter & Morton Coleman. 2007. Apoptosis, Senescence, and Cancer. Apoptosis, Senescence, and Cancer 511 536 .
Scott J. Rodig, Jeremy S. Abramson, Geraldine S. Pinkus, Steven P. Treon, David M. Dorfman, Henry Y. Dong, Margaret A. Shipp & Jeffery L. Kutok. (2006) Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H). Clinical Cancer Research 12:23, pages 7174-7179.
Crossref
Thomas A. Waldmann & John C. Morris. 2006. Cancer Immunotherapy. Cancer Immunotherapy 83 131 .
Richard R. Furman, Morton Coleman, Daniel Muss & John P. Leonard. 2006. Hodgkin’s and Non-Hodgkin’s Lymphoma. Hodgkin’s and Non-Hodgkin’s Lymphoma 221 250 .
Thomas S. Lin & John C. Byrd. 2006. Oncology. Oncology 1210 1228 .
Eric T. Wong. (2005) Management of Central Nervous System Lymphomas Using Monoclonal Antibodies: Challenges and Opportunities. Clinical Cancer Research 11:19, pages 7151s-7157s.
Crossref
Philip Kuriakose. (2017) Targeted Therapy for Hematologic Malignancies. Cancer Control 12:2, pages 82-90.
Crossref
Tadeusz Robak. (2005) Alemtuzumab in the Treatment of Chronic Lymphocytic Leukemia. BioDrugs 19:1, pages 9-22.
Crossref
Thomas S. Lin, Mollie Moran, Margaret Lucas, Sharon Waymer, Sara Jefferson, Diane B. Fischer, Michael R. Grever & John C. Byrd. (2004) Antibody therapy for chronic lymphocytic leukemia: a promising new modality. Hematology/Oncology Clinics of North America 18:4, pages 895-913.
Crossref
Travis D Archuleta & James O Armitage. (2004) Advances in follicular lymphoma. Seminars in Oncology 31, pages 66-71.
Crossref
Cristina Gasparetto. (2017) Stem Cell Transplantation for Multiple Myeloma. Cancer Control 11:2, pages 119-129.
Crossref
John C. Byrd, Stephan Stilgenbauer & Ian W. Flinn. (2004) Chronic Lymphocytic Leukemia. Hematology 2004:1, pages 163-183.
Crossref
Y Gazitt. (2003) Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-specific antibodies. Leukemia 18:1, pages 1-10.
Crossref
George J. Weiner & Brian K. Link. 2004. Treatment of Leukemia and Lymphoma. Treatment of Leukemia and Lymphoma 229 253 .
Thomas S. Lin & John C. Byrd. 2004. Treatment of Leukemia and Lymphoma. Treatment of Leukemia and Lymphoma 127 167 .
Thomas S. Lin, Margaret S. Lucas & John C. Byrd. 2004. Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia 269 298 .
John P. LeonardMorton ColemanJamie C. KetasAmy ChadburnScott ElyRichard R. FurmanWilliam A. WegenerHans J. HansenHeather ZiccardiMichael EschenbergUrte GaykoAlessandra CesanoDavid M. Goldenberg. (2003) Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma. Journal of Clinical Oncology 21:16, pages 3051-3059.
Crossref
Paul Moreton & Peter Hillmen. (2003) Alemtuzumab therapy in B-cell lymphoproliferative disorders. Seminars in Oncology 30:4, pages 493-501.
Crossref
Abby B. Siegel, David M. Goldenberg, Alessandra Cesano, Morton Coleman & John P. Leonard. (2003) CD22-directed monoclonal antibody therapy for lymphoma. Seminars in Oncology 30:4, pages 457-464.
Crossref
Robert O. Dillman. (2003) Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. Seminars in Oncology 30:4, pages 434-447.
Crossref
Régis T. Costello, J. Rey, C. Fauriat, J.-A. Gastaut & D. Olive. (2003) New approaches in the immunotherapy of haematological malignancies. European Journal of Haematology 70:5, pages 333-345.
Crossref
Taghi ManshouriKim-anh DoXuemei WangFrancis J. GilesSusan M. O'BrienHelen SafferDeborah ThomasIman JilaniHagop M. KantarjianMichael J. KeatingMaher Albitar. (2003) Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101:7, pages 2507-2513.
Crossref
Scot Ebbinghaus, Robert K. Oldham & Robert O. Dillman. 2003. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy 615 674 .
Robert O. Dillman. 2003. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy 329 390 .
Igor Espinoza-Delgado & Dan L. Longo. 2003. Allogeneic Stem Cell Transplantation. Allogeneic Stem Cell Transplantation 83 99 .
. (2001) Current Awareness in Hematological Oncology. Hematological Oncology 19:4, pages 159-166.
Crossref
Oliver W. Press, John P. Leonard, Bertrand Coiffier, Ronald Levy & John Timmerman. (2001) Immunotherapy of Non-Hodgkin's Lymphomas. Hematology 2001:1, pages 221-240.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.